In turn, the previously reported positive prognostic significance of ERK1/2pathway activation in breast cancer was confirmed in two gene expressiondatasets for patients receiving combination treatment with taxanes andanthracyclines: GSE25066 (paclitaxel, 5-fluorouracil, cyclophosphamide,doxorubicin or epirubicin in adjuvant and neoadjuvant regimens) and GSE20194(paclitaxel, 5-fluorouracil, cyclophosphamide, doxorubicin in combination inneoadjuvant regimen),(Fig. 6C,D). The gene discussed is MAPK3; the disease is breast carcinoma.